ArrePath announced today that it has raised $20 million in seed financing to advance its proprietary, machine learning (ML)-based platform for the discovery of new classes of anti-infectives to overcome antimicrobial resistance (AMR).
At ArrePath, we believe our team is everything. As part of our season introducing our team members, say hello to Gayatri, who joined ArrePath at the beginning of 2022.
We continue to grow and hire, please visit: https://arrepath.com/careers/
Fabulous opportunities for early career Data Scientists and Computer Vision scientists to join a great team in a great company, applying the latest approaches in AI / ML in drug discovery.
Please visit https://arrepath.com/careers/ for more details.
#AI #ML #Hiring
A warm welcome to Dr Paul Lukacs from all of us at ArrePath!
We look forward to working with Paul as we continue to deliver on our mission to harness the power of imaging technologies and AI / ML in the discovery of new anti-infectives.
#AI #ML #drugdiscovery #antiinfectives
New CDC Report on impact of #COVID on #AMR: “This setback can and must be temporary. The COVID-19 pandemic has unmistakably shown us that antimicrobial resistance will not stop if we let down our guard; there is no time to waste,” #AntimicrobialResistance
The US government’s @BARDA & @wellcometrust will provide up to an additional $370M to @CARB_X to support a portfolio of therapeutics, diagnostics and preventatives to address the global health threat of antimicrobial resistance #AMR.
➡️ Announcement: https://bit.ly/3a2WSkx
“We’re going to get this over the finish line.” Thank you @MichaelBennet for your optimism and determination to see PASTEUR passed. #SquashSuperbugs
Manage Cookie Consent
The technical storage or access is strictly necessary for the legitimate purpose of enabling the use of a specific service explicitly requested by the subscriber or user, or for the sole purpose of carrying out the transmission of a communication over an electronic communications network.
The technical storage or access is necessary for the legitimate purpose of storing preferences that are not requested by the subscriber or user.
The technical storage or access that is used exclusively for statistical purposes.The technical storage or access that is used exclusively for anonymous statistical purposes. Without a subpoena, voluntary compliance on the part of your Internet Service Provider, or additional records from a third party, information stored or retrieved for this purpose alone cannot usually be used to identify you.
The technical storage or access is required to create user profiles to send advertising, or to track the user on a website or across several websites for similar marketing purposes.